Angiotensin inhibition after myocardial infarction: Does drug class matter?

Journal of General Internal Medicine

Volumn 21, Issue 12, 2006, Pages 1242-1247

  Winkelmayer, Wolfgang C ^a   Fischer, Michael A ^a   Schneeweiss, Sebastian ^a   Levin, Raisa ^a   Avorn, Jerry ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Coronary heart disease; Epidemiology; Health services and outcomes research; Preventive cardiology

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; TICLOPIDINE; WARFARIN;

AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG CLASSIFICATION; DRUG USE; FEMALE; HEALTH CARE COST; HEART FAILURE; HEART INFARCTION; HORMONE INHIBITION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORTALITY; PRESCRIPTION; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COHORT STUDIES; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; PRESCRIPTIONS, DRUG; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 33750507247     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1111/j.1525-1497.2006.00590.x     Document Type: Article

References (25)

1. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669-77.
2. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The acute infarction ramipril efficacy (AIRE) study investigators. Lancet. 1993;342:821-8.
3. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril cardiac evaluation (TRACE) study group. N Engl J Med. 1995;333:1670-6.
4. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Heart outcomes prevention evaluation study investigators. Lancet. 2000;355:253-9.
5. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med. 1992;117:234-42.
6. McMurray JJ, McGuire A, Davie AP, Hughes D. Cost-effectiveness of different ACE inhibitor treatment scenarios post-myocardial infarction. Eur Heart J. 1997;18:1411-5.
7. Golan L, Birkmeyer JD, Welch HG. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med. 1999;131:660-7.
8. Weintraub WS, Cole J, Tooley JF. Cost and cost-effectiveness studies in heart failure research. Am Heart J. 2002;143:565-76.
9. Rosen AB, Hamel MB, Weinstein MC, Cutler DM, Fendrick AM, Vijan S. Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med. 2005;143:89-99.
10. Grossman E, Messerli FH, Neutel JM. Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors? Arch Intern Med. 2000;160:1905-11.
11. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial [see comment]. Lancet. 2003;362:772-6.
12. Ramsay LE, Yeo WW. ACE inhibitors, angiotensin II antagonists and cough. The Losartan cough study group. J Hum Hypertens. 1995;9 (suppl. 5):S51-S54.
13. www.drugstore.com. Accessed June 23, 2005.
14. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349:1893-906.
15. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal trial in myocardial infarction with angiotensin II antagonist losartan. Lancet. 2002;360:752-60.
16. Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J. 2004;148:99-104.
17. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58:323-37.
18. McMurray JJ. Angiotensin II receptor antagonists for the treatment of heart failure: what is their place after ELITE-II and Val-HeFT? J Renin Angiotensin Aldosterone Syst. 2001;2:89-92.
19. Morimoto T, Gandhi TK, Fiskio JM, et al. Development and validation of a clinical prediction rule for angiotensin-converting enzyme inhibitor-induced cough. J Gen Intern Med. 2004;19:684-91.
20. Fischer MA, Schneeweiss S, Avorn J, Solomon DH. Medicaid priorauthorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med. 2004;351:2187-94.
21. Fischer MA, Choudhry NK, Winkelmayer WC. Impact of Medicaid prior authorization policies on use of angiotensin receptor blockers [Abstract]. J Gen Intern Med. 2006;21:S70.
22. McDonald MA, Simpson SH, Ezekowitz JA, Gyenes G, Tsuyuki RT. Angiotensin receptor blockers and risk of myocardial infarction: systematic review. BMJ. 2005;331:873.
23. Lee VC, Rhew DC, Dylan M, Badamgarav E, Braunstein GD, Weingarten SR. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med. 2004;141:693-704.
24. Epstein BJ, Gums JG. Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations. Ann Pharmacother. 2005;39:470-80.
25. Pilote L, Abrahamowicz M, Rodrigues E, Eisenberg MJ, Rahme E. Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect? Ann Intern Med. 2004;141:102-12.